{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310670","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.561561+00:00","generated_at":"2026-05-16T14:03:06.258778+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call","bullets":["Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.","Specific efficacy, safety, and biomarker outcomes not available from provided text.","Conference call hosted by CEO Nello Mainolfi and CMO Jared Gollob.","KT-621 is first-in-class oral STAT6 degrader targeting Th2-driven inflammation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310670","json":"https://secwatch.observer/filing/0001193125-25-310670.json","markdown":"https://secwatch.observer/filing/0001193125-25-310670.md","text":"https://secwatch.observer/filing/0001193125-25-310670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/0001193125-25-310670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/d77337d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:03:06.258778+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}